PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

SUCRAID
(sacrosidase)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS
Sucraid (sacrosidase) Oral Solution is indicated as oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).

COVERAGE CRITERIA
The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of congenital sucrase-isomaltase deficiency

AND

- The diagnosis of congenital sucrase-isomaltase deficiency was confirmed by small bowel biopsy
  OR
- The diagnosis of congenital sucrase-isomaltase deficiency was confirmed by genetic testing
  OR
- The diagnosis of congenital sucrase-isomaltase deficiency was confirmed by sucrose hydrogen breath test

Quantity Limits apply.

QUANTITY LIMIT

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

Drug	**1 Month Limit***	**3 Month Limit***
Sucraid Multiple-Dose Bottle (Each bottle contains 4 oz [118 mL total])	354 mL / 25 days	1062 mL / 75 days
Sucraid Single-Use Container (Each carton contains 150 single-use containers of 2 mL each [300 mL total])	300 mL/ 21 days	900 mL/ 63 days

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing OR the duration of 21 days is used for a 25-day fill period and 63 days is used for a 75-day fill period to allow time for refill processing.*

REFERENCES
1. Sucraid [package insert]. Vero Beach, FL: QOL Medical, LLC; May 2022.

2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed September 2, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed September 2, 2021.
4. National Organization for Rare Disorders (NORD). Congenital Sucrase-Isomaltase Deficiency. 2005. Available at https://rarediseases.org. Accessed September 2021.
5. Genetic and Rare Diseases Information Center. Congenital sucrose-isomaltase deficiency. 2020. Available at https://rarediseases.info.nih.gov. Accessed September 2021.